Konstantynów ?ódzki, Poland, - October 8, 2021 – Mabion S.A. (WSE: MAB), a biotechnology company headquartered in Poland, today announced the signing of a contract manufacturing agreement with Novavax for the large-scale production of the protein antigen used in Novavax’ recombinant nanoparticle protein-based COVID?19 vaccine candidate, NVX-CoV2373. The four-year deal provides production capacity at Mabion’s Poland-based facility through 2026.
Konstantynów ?ódzki, Poland, March 3rd, 2021 – Mabion (Warsaw Stock Exchange (WSE): MAB), a
Mylan has struck a deal to commercialise a version of Roche’s Mabthera in Europe made by Polish biotech Mabion using a 2,500L disposable bioreactor system.